September 12, 2014

Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations

Symetis joins industry leaders Edwards Lifesciences and Medtronic as only companies to offer both transapical and transfemoral options for transcatheter aortic heart valve delivery

Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of ACURATE neo™, its 15F compatible transfemoral TAVI system. Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer.
PDF Download

 


 

read more »

September 02, 2014

Evolva’s first half results show higher revenues and a strong balance sheet

First products on market.

Reinach, Switzerland, 2 September 2014 – Evolva Holding SA (SIX: EVE) today announces its financial results for the period 1 January to 30 June 2014. The condensed half-year accounts are available on Evolva’s website.
PDF Download - English Version
PDF Dowload - German Version
PDF Download - Half Year Report in English
PDF Download - Presentation in English

read more »

August 29, 2014

Biotie: Selincro enters the market in Germany

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Germany. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.
PDF Download

read more »

August 15, 2014

Evolva & Cargill Announce Publication Of Stevia Reb M Patent Application

Evolva and Cargill are pioneering the production of great tasting, next-generation sweeteners via fermentation

Evolva Holding SA (SIX:EVE) announced that its patent application (WO 2014122227) on a process to efficiently and sustainably produce next-generation sweeteners via fermentation, including Rebaudioside M (“Reb M”), has now published. The patent application was originally filed on February 6, 2013.
PDF Download - English Version
PDF Dowbload - German Version

read more »

August 04, 2014

Evolva strengthens in-silico capabilities with acquisition of Prosarix

Evolva Holding SA (SIX: EVE) today announces the acquisition of Cambridge, UK based Prosarix Ltd., a leading in silico (computational) modelling company focusing on small molecule identification, design, biosynthesis and function.
PDF Download - English Version
PDF Download - German Version

read more »

July 30, 2014

Biotie updates outlook on tozadenant and SYN120

Tozadenant to advance into Phase 3 in Parkinson's disease within Biotie's proprietary portfolio and SYN120 to advance into Phase 2 in Parkinson's disease dementia, further strengthening Biotie's presence in Parkinson's disease space

Biotie has decided to advance tozadenant, its adenosine A2a receptor antagonist for Parkinson's disease, into Phase 3 development as part of the Company's proprietary portfolio. Preparations for Phase 3 development are ongoing, and it is expected that the Phase 3 clinical studies can commence recruitment in H1 2015, as originally planned.
PDF Download

read more »

July 24, 2014

Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding

Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with its vascular adhesion protein-1 (VAP-1) antibody, BTT1023, in primary sclerosing cholangitis (PSC). PSC is a chronic and progressive orphan fibrotic disease for which there are currently no approved therapeutic treatments. The study will be conducted in the UK and is expected to start recruiting patients by the end of 2014.
PDF Download

read more »

July 22, 2014

Biotie: Selincro enters the market in Spain

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Spain. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.
PDF Download

read more »

July 10, 2014

Biotie: Selincro receives positive draft guidance from UK's NICE

Biotie Therapies (Biotie) announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom's health technology assessment authority, has issued draft guidance recommending the use of Selincro (nalmefene) within the conditions of its marketing authorization in the National Health Service (NHS) in England. The draft guidance is open for comments until July 29, and final guidance is expected in November 2014.
PDF Download

read more »

July 08, 2014

Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology

Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson's disease patients experiencing end of dose wearing off have been published in Lancet Neurology (Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014; published online July 7. http://dx.doi.org/10.1016/S1474-4422(14)70148-6). The Phase 2b study was an international, randomised, double blind, placebo-controlled, parallel group, dose finding study in 420 levodopa-treated patients with end of dose wearing off (i.e at least 2.5 hours off time per day). Patients received either 60mg, 120mg, 180mg or 240mg tozadenant or matching placebo twice daily for 12 weeks.  The primary outcome was a change from baseline to week 12 in hours per day spent in the off-state, assessed from patient diaries. As previously disclosed, the study demonstrated that tozadenant, when compared to placebo, decreased levodopa related motor fluctuations.
PDF Download

read more »

June 18, 2014

MerLion completes recruitment in Finafloxacin phase II cUTI trial

MerLion Pharmaceuticals (MerLion) announced today that it has completed the planned recruitment into its Phase II trial in patients hospitalized with Complicated Urinary Tract Infection, including pyelonephritis (“cUTI”) in Germany and Poland.
PDF Download

read more »

May 28, 2014

Evolva starts commercial resveratrol production

Evolva Holding SA (SIX: EVE) today announces the start of commercial production of its resveratrol ingredient. Evolva has succeeded in optimising and scaling the fermentation process, resulting in competitive production costs that allow a commercial launch. Evolva’s resveratrol is high-purity (>98% pure trans-Resveratrol), with a controlled and reliable supply chain, produced from natural and sustainable feedstocks. It is the only resveratrol product made by brewing.
PDF Download - English Version
PDF Download - German Version

read more »

May 27, 2014

Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014

Biotie Therapies today announced that patient enrollment into the Phase 2 study investigating nepicastat for cocaine dependence has been completed ahead of schedule. The 11-week, 179-patient study is being conducted at 10 US clinics under a Collaborative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA) at the US National Institutes of Health. Top-line results from the study are expected around the end of 2014
PDF Download

read more »

May 26, 2014

MerLion Announces a Significant Milestone in the Development of Finafloxacin for Treatment of Acute Otitis Externa

MerLion Pharmaceuticals (MerLion) announced today that its North American partner has achieved a significant regulatory milestone in the development of finafloxacin for the treatment of acute otitis external (bacterial infection of the outer ear).
PDF Download

read more »

May 21, 2014

Evolva achieves key milestone in Stevia project with Cargill

Cargill and Evolva Holding SA (SIX: EVE) today announced the achievement of a technical milestone in their joint development program of fermentation-based minor steviol glycosides - the compounds responsible for the sweet taste in the stevia leaf. The milestone is an enabling step in bringing additional great tasting stevia-based sweeteners to market in a cost effective and sustainable way for food and beverage manufacturers.
PDF Download - English Version
PDF Download - German Version

read more »

May 16, 2014

Telormedix’s Vesimune Successfully Completes Phase II for Carcinoma In Situ of the Bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.
PDF Download

read more »

March 27, 2014

RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic Monoclonal Antibodies Targeting GPCR Receptors

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi’s iCAPS platfrom

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi's lead asset, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb), and the discovery and development of new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target. In addition, RuiYi expanded the leadership team, appointing Erik Karrer, Ph.D. as chief scientific officer and Brian Campion, Ph.D. as vice president of business development.
PDF Download

read more »

March 21, 2014

Biotie to regain global rights to tozadenant from UCB

• Tozadenant is transitioning into Phase 3 development for Parkinson's disease • Biotie to host a conference call for analysts and media today at 14:00 Central European time

Biotie Therapies Corp. announced today that UCB Pharma S.A. (UCB) will return global rights to tozadenant to Biotie. Tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor, has delivered clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation parameters, in a 420 patient Phase 2b study completed in December 2012. Tozadenant is expected to start recruitment for the Phase 3 program in H1 2015.
PDF Download

read more »

March 12, 2014

Novimmune appoints Andrew J. Oakley as CFO

Novimmune SA announced today that Andrew J. Oakley has joined the company as Chief Financial Officer.
PDF Download

read more »

February 26, 2014

Evolva successfully places new shares

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) has successfully completed its placement of shares which was announced yesterday. Evolva has sold 27,000,000 new shares via an accelerated bookbuild process by way of a private placement in Switzerland and outside of Switzerland in accordance with applicable securities laws. The shares have been placed at a price of CHF 1.37 per share, representing a discount of 4.9% to the closing price of 25 February 2014.
PDF Download - English Version
PDF Download - German Version

read more »

February 25, 2014

Evolva reports preliminary, unaudited financial results for 2013 and announces launch of share placement

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) today announces its preliminary, unaudited financial results for 2013. In 2013, the Company had total revenues of CHF 8.7 million compared with CHF 7.0 million in 2012 and generated an operational loss of CHF 17.7 million (2012: CHF 20.0 million). The cash outflow from operations and investment amounted to CHF 13.6 million (2012: CHF 14.0 million). At the end of 2013, the Company had CHF 29.3 million in cash and cash equivalents. Each of these parameters is within the guidance provided in August 2013. The audited financial report for 2013 will be released on 8 April 2014, as previously announced.
PDF Download - English Version
PDF Download - German Version
 

read more »

February 18, 2014

Novimmune announces closing of CHF 60 million financing

Novimmune SA announced that it has closed a Series B financing for CHF 60 million ($66 million). London-based Rosetta Capital Limited led the round with participation of new private investors as well as existing investors.
PDF Download

read more »

February 18, 2014

SynAffix raises Series A investment round to advance its GlycoConnect™ technology for creating next-generation ADCs

SynAffix B.V., a protein engineering company focusing on the creation of next-generation Antibody-Drug Conjugates (ADCs), today announced the completion of its Series A investment round. Financial details have not been disclosed.
PDF Download

read more »

February 13, 2014

EBM and ewb increase wind energy production

EBM and Energie Wasser Bern (ewb) continue to expand their share of energy production from renewable sources. Through their joint venture company "leading swiss renewables AG" (LSR) and with the support of Aravis they have acquired two French wind parks with a total capacity of 18 Megawatts (MW).
PDF Download - English Version
PDF Download - German Version

read more »

February 10, 2014

Evolva announces collaboration with L’Oréal

Evolva Holding SA (SIX: EVE) announced that it has signed a collaboration agreement with L’Oréal for the co-development of novel biosynthetic production routes for an undisclosed ingredient with broad applications in the cosmetics industry. Evolva and L’Oréal will apply Evolva’s fermentation technology platform to develop and optimise yeast strains for the sustainable, cost-effective production of this strategically important cosmetics ingredient.
PDF Downloan - English Version
PDF Download - German Version

read more »

January 09, 2014

ARAVIS strengthens life science team with three important appointments

Dr Dani Bach (formerly of Index Ventures) joins as Managing Partner, Dr Jacques Mizrahi joins in a consulting role as Venture Partner and Kadri Vunder (formerly LSVenture) as a Partner

Aravis, the first independent Swiss on-shore private equity house and an established investor in the life science and renewable energy spaces, today announced the appointment of three new members of the life science investment team.
PDF Download

read more »